Liver transplantation and hepatitis C: Will understanding the interleukin-28B polymorphisms improve outcomes?

Liver Transplantation

Volumn 17, Issue 3, 2011, Pages 219-221

  McCaughan, Geoffrey W ^a   Shackel, Nicholas A ^a   Bowen, David G ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN;

ALLELE; ANTIVIRAL THERAPY; CYTOKINE PRODUCTION; EDITORIAL; GENETIC ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER DISEASE; LIVER TRANSPLANTATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VIRUS REPLICATION;

ANTIVIRAL AGENTS; GENETIC PREDISPOSITION TO DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HUMANS; INTERLEUKINS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; POLYMORPHISM, GENETIC; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952390177     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22252     Document Type: Editorial

References (24)

1. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
2. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
3. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
4. Iadonato SP, Katze MG., Genomics: hepatitis C virus gets personal. Nature 2009; 461: 357-358.
5. Shackel NA, Bowen DG, McCaughan GW., Snipping away at hepatitis C. HEPATOLOGY 2010; 51: 703-705.
6. Asrani SK, Kim WR., Predicting response to pegylated interferon/ ribavirin-based therapy in genotype 1 chronic hepatitis C patients: results of 3 independent genome-wide association studies. Gastroenterology 2010; 138: 1622-1624.
7. Aghemo A, Colombo M., Genetic variation in interleukin-28B predicts hepatitis C treatment-induced viral clearance in genotype 1 patients: the dawn of a new era? Gastroenterology 2010; 138: 2546-2549.
8. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827.
9. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.
10. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
11. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 1586-1592.
12. Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. HEPATOLOGY 2010; 52: 1216-1224.
13. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. HEPATOLOGY 2010; 52: 1888-1896.
14. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. HEPATOLOGY 2010; 52: 421-429.
15. Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, Miki D, et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 2010; 53: 439-443.
16. Thompson AJ, Clark PJ, Zhu M, Zhu Q, Ge D, Sulkowski MS, et al. Genome wide-association study identifies IL28B polymorphism to be associated with baseline ALT and hepatic necro-inflammatory activity in chronic hepatitis C patients enrolled in the IDEAL study [abstract]. HEPATOLOGY 2010; 52 (suppl 1): 1220A.
17. Thompson AJ, Clark PJ, Fellay J, Muir AJ, Tillmann HL, Patel K, et al. IL28B genotype is not associated with advanced hepatic fibrosis in chronic hepatitis C patients enrolled in the IDEAL study [abstract]. HEPATOLOGY 2010; 52 (suppl 1): 437A.
18. Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. HEPATOLOGY 2010; 51: 1904-1911.
19. Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carrillo ED, Berg T, et al. Relationship between the Interleukin-28b gene polymorphism and the histological severity of Hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl 2011; 17:289-298.
20. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-1585.
21. Charlton MR, Thompson AJ, Veldt BJ, Watt KD, Tillmann HL, Poteruchal JJ, et al. IL28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with HCV infection [abstract]. HEPATOLOGY 2010; 52 (suppl 1): 320A.
22. Coto-Llerena M, Perez-del-Pulgar S, Crespo G, Gonzalez P, Mensa L, Dragun J, et al. IL28B polymorphisms may improve response to hepatitis C therapy after liver transplantation [abstract]. HEPATOLOGY 2010; 52 (suppl 1): 867A.
23. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-68. (Pubitemid 36104710)
24. Thomas E, Gonzalez VD, Noureddin M, Rotman Y, Liang TJ., Characterization of the interferon lambda (IL28/29) antiviral pathway in cell culture, human and chimpanzee models of HCV infection [abstract]. HEPATOLOGY 2010; 52 (suppl 1): 741A.